Takeda Pharma Files 6-K for October 2025 Reporting
Ticker: TKPHF · Form: 6-K · Filed: Oct 1, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Takeda filed its 6-K for Oct 2025, confirming 20-F for annual reports.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on October 1, 2025, reporting as a foreign private issuer. The filing indicates Takeda will file its annual reports under Form 20-F. The report covers information furnished for the month of October 2025.
Why It Matters
This filing serves as an update for investors regarding Takeda's reporting status as a foreign private issuer and its commitment to filing under the Form 20-F for annual reports.
Risk Assessment
Risk Level: low — This is a routine reporting form for a foreign private issuer and does not contain specific financial or operational news.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer of the 6-K report
- 001-38757 (company) — SEC File Number for Takeda
- 20251001 (date) — Filing date and period of report
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, providing information that the registrant makes or is required to make public pursuant to the laws of its home country.
Which form does Takeda Pharmaceutical Company Limited use for its annual reports?
Takeda Pharmaceutical Company Limited indicates it files its annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
The filing date, as of date, and conformed period of report is October 1, 2025.
What is Takeda's principal executive office address?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
Is Takeda submitting this Form 6-K in paper format?
The filing does not indicate that Takeda is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7).
Filing Stats: 1,243 words · 5 min read · ~4 pages · Grade level 16.7 · Accepted 2025-10-01 09:20:18
Filing Documents
- form6k_100125.htm (6-K) — 24KB
- 0001395064-25-000145.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date October 1, 2025 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Takeda Provides Update on Cell Therapy Research OSAKA, Japan and CAMBRIDGE, Massachusetts, October 1, 2025 – Takeda (TSE4502NYSETAK) today announced that as part of a strategic portfolio prioritization process, the company has made the decision to discontinue its cell therapy efforts. Takeda will seek an external partner to leverage its cell therapy platform technologies and to further advance the company's research and clinic-ready programs in this field. The company has no current active clinical trials utilizing cell therapy technology. Takeda will refocus near-term investments into programs that it believes can deliver transformative therapies to patients at increased speed and scale. The company's preclinical programs utilizing its in-focus modalities, including small molecules, biologics, and antibody-drug conjugates, are advancing novel and highly innovative therapeutic candidates. Takeda's preclinical research programs will continue to benefit from the novel insights gained from its cell therapy research. In the second quarter of the fiscal year ending March 31, 2026 (FY2025), Takeda expects to recognize an impairment loss of approximately JPY 58.0 billion, primarily related to intangible assets associated with the gamma delta T-cell therapy platform. The majority of this impact is expected to be absorbed by the JPY 50.0 billion of impairment losses on intangible assets associated with products, including in-process RD, included in Takeda's full-year consolidated forecast for FY2025 announced on May 8, 2025. Takeda will continue to assess any other related impacts and, to the extent necessary, r
Forward-Looking Statements
Forward-Looking Statements This statement and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States competitive pressures and developments changes to applicable laws and regulations, including global health care reforms challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof uncertainty of commercial success for new and existing products manufacturing difficulties or delays fluctuations in interest and currency exchange rates claims or concerns regarding the safety or efficacy of marketed products or product candidates the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business the timing and impact of post-merger integration efforts with acquired companies the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s) the extent to which our internal energy conservation measures and future advancements in renew